CLINICAL_TRIALS
trial_result
· 2024-09-19
Clinical Trial Update: Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Adult T Cell Lymphoma (ATL) [Phase 2]
Summary
Phase 2 trial evaluating oral HBI-8000 in relapsed or refractory adult T-cell leukemia/lymphoma reports efficacy and safety results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: HUYABIO International, LLC. | Conditions: Adult T-Cell Lymphoma (ATL) | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19